Related Articles
Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)
Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2‑positive breast cancer in Japan
Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer
Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB